📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-31 18:09
395 analysed today
FollowTelegram
395
Today
149,796
All-time analysed
42,945
Positive
6,666
Negative
91,495
Neutral
8,622
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
30 announcements match the current filters (relevance ≥ 5).
US Court grants preliminary approval for Indegene's max $4.72M class action lawsuit settlement
Indegene's US subsidiary, Indegene, Inc., has received preliminary approval from the US District Court, District of New Jersey, for a class action settlement under the Telephone Consumer Protection Act. The settlement framework caps the maximum settlement fund at approximately USD 4.72 million (~₹39.5 crore), structured on a claims-made basis with USD 250 payable per approved claim. Final approval hearing is scheduled for 12 January 2027 following the claims submission deadline on 9 December 2026. Given Indegene's TTM net profit of ₹401 crore, the capped liability represents less than 10% of annual profits and removes legal uncertainty.
Confidence: HIGH
What changedThe US District Court granted preliminary approval to the settlement agreement, setting formal timelines for class notices, claims submission, and final approval.
Why it mattersCaps the legal liability of Indegene's US subsidiary at a maximum of USD 4.72 million, minimizing financial uncertainty relative to its ₹401 crore TTM net profit.
Maximum Settlement Fund: USD 4.72 millionPayment per eligible claim: USD 250Claims deadline: 9 December 2026Final approval hearing date: 12 January 2027
📅 Short termProvides clarity and sets a clear legal timeline without immediate cash outflow, as no pre-funding or escrow is required.
📈 Long termClears an overhang from legacy class action litigation in the core US geography.
⚠ Risk flags
- Settlement remains subject to final court approval following notice and objection periods.
Key Highlights
US District Court granted preliminary approval on 27 August 2026 for the proposed class action settlement
Maximum settlement fund capped at approximately USD 4.72 million, with USD 250 payable per eligible claim
Class notice to be issued by 10 September 2026; claims and objection deadline set for 9 December 2026
Final approval hearing scheduled for 12 January 2027
👀 What to Watch
Track the claims submission deadline on 9 December 2026 and the final court approval hearing on 12 January 2027 to assess actual cash outflow.
Indegene Agrees to Settle US Class Action Fax Lawsuit with Max Fund Capped at $4.72M
Indegene Limited's US subsidiary, Indegene, Inc., has finalized terms for a definitive settlement agreement regarding a class-action lawsuit under the US TCPA concerning February 2020 fax communications. The agreement establishes a contractual maximum settlement fund of approximately USD 4.72 million (calculated at USD 250 per eligible claim across 18,851 unique fax numbers). The settlement operates on a claims-made and reversionary basis, meaning actual cash outflow will depend on verified claims and unspent funds will revert to the company without requiring upfront escrow. Against Indegene's TTM PAT of ₹401 Cr, the maximum exposure represents around 10%, effectively capping a long-standing legal overhang.
Confidence: HIGH
What changedIndegene has moved from mediation to authorizing execution of a definitive settlement agreement, capping its TCPA class action exposure at a maximum of USD 4.72M.
Why it mattersResolves legal uncertainty dating back to 2020 at a manageable maximum financial impact (approx. ₹39-40 Cr max vs ₹401 Cr TTM PAT), with actual cash outflow likely lower due to the reversionary structure.
Maximum Settlement Fund: USD 4.72 millionPer-claim compensation: USD 250Certified Class Size: 18,851 unique fax numbersSettlement Admin Cost: USD 42,559Max Exposure vs TTM PAT: ~10%
📅 Short termRemoves legal uncertainty; market reaction should be neutral-to-mildly positive as the liability is now strictly defined and claims-dependent.
📈 Long termEliminates a historical pre-IPO litigation overhang from 2020 without material disruption to balance sheet or growth strategy.
⚠ Risk flags
- Subject to formal execution and final approval by the U.S. District Court, District of New Jersey
Key Highlights
Maximum settlement fund capped at approximately USD 4.72 million (USD 250 per eligible claim)
Class consists of approximately 18,851 unique fax numbers across 18,869 transmissions
Settlement is on a claims-made and reversionary basis; no upfront full funding/escrow required
Estimated settlement administration cost agreed at approximately USD 42,559
Definitive agreement finalized by company and awaiting formal execution and US District Court approval
👀 What to Watch
Track subsequent filings for US District Court preliminary and final approval milestones, as well as the final quantified claims impact reported in future quarterly financials.
39.7% YoY Revenue Growth in Q1 FY27; Active Clients Cross 100 Milestone
Indegene reported a strong start to FY27 with Q1 revenue reaching ₹1,063.1 cr, a 39.7% increase year-on-year and 6% quarter-on-quarter. The company successfully diversified its client base, with accounts outside the top 20 global pharma firms now contributing over 33% of total revenue. Key deal wins include one $3M-$5M contract and four $1M-$3M contracts, alongside a milestone of reaching 105 active clients. Management remains confident in FY27 being stronger than FY26, driven by AI-integrated commercialization services and expansion into new therapeutic areas.
Confidence: HIGH
What changedIndegene has delivered its strongest Q1 sequential growth in four years and successfully crossed the 100-active-client milestone while diversifying revenue away from its top 20 clients.
Why it mattersThe results validate Indegene's specialized life-sciences model, showing that it can grow significantly faster than traditional IT services by embedding itself in the commercial 'revenue engine' of pharma companies rather than just the 'cost side'.
Q1 FY27 Revenue: ₹1,063.1 crYoY Revenue Growth: 39.7%Q1 Revenue vs TTM Revenue: 30.3%Active Clients: 105Revenue per Employee (TTM): $77,000Top 20 Client Concentration: 65.5%
📅 Short termThe stock may see positive sentiment following the robust 39.7% YoY growth and management's optimistic outlook for FY27 being stronger than FY26.
📈 Long termIndegene is structurally positioning itself to benefit from the 'patent cliff' facing big pharma, as companies require more efficient, AI-driven commercialization for wider drug portfolios.
⚠ Risk flags
- High client concentration with top 20 pharma still contributing 65.5% of revenue
- Potential pricing pressures from the US Inflation Reduction Act (IRA) impacting client spend
- Talent attrition and wage inflation in specialized life-sciences roles
Key Highlights
Q1 FY27 revenue stood at ₹1,063.1 cr (INR 10,631 million), representing 39.7% YoY growth.
Active client base reached 105, with two new customers added to the $10M-$25M annual revenue bucket.
Secured 5 significant new deals: one in the $3M-$5M range and four in the $1M-$3M range.
Revenue per employee maintained at an industry-leading level of approximately $77,000 on a TTM basis.
Non-top 20 pharma accounts now contribute more than one-third of total company revenues.
👀 What to Watch
Watch for the execution of the 'Agentic AOR' and 'Tectonic' engagements as they move from proof-of-concept to larger scale. Monitor if the company can maintain its 17-18% operating margins while investing in AI talent and integrating recent UK and US acquisitions.
39.7% YoY Revenue Growth in Q1 FY27; Active Clients Reach 105
Indegene reported a strong start to FY27 with Q1 revenue growing 39.7% YoY to ‑1,063.1 Cr, driven by robust demand in Enterprise Commercial Solutions. While EBITDA margins contracted to 16.9% from 20.2% a year ago, PAT saw a sharp sequential recovery of 45.9% to ‑116.2 Cr. The company successfully diversified its client base, adding 35 active clients YoY to reach 105, and improved its Revenue per Employee to a record $77.1K. Cash reserves remain healthy at ‑1,460.2 Cr, representing approximately 11.6% of the current market capitalization.
Confidence: HIGH
What changedIndegene has significantly broadened its client base beyond the top 20 global biopharma firms while achieving its highest-ever revenue per employee.
Why it mattersThe shift toward a more diversified client base reduces concentration risk, while the growth in outcome-aligned revenue (now ~60%) suggests a transition toward higher-value, technology-led delivery.
Q1 Revenue: ‑1,063.1 CrYoY Revenue Growth: 39.7%EBITDA Margin: 16.9%Revenue per Employee: $77.1KCash vs Market Cap: ~11.6%Active Clients: 105
📅 Short termThe strong top-line growth and sequential PAT recovery are likely to be viewed positively by the market in the coming weeks.
📈 Long termThe structural shift toward GenAI-integrated commercialization and a wider client pyramid positions the company to capture a larger share of the life sciences outsourcing market.
⚠ Risk flags
- EBITDA margin compression (down 330 bps YoY)
- High industry concentration (91.6% revenue from Biopharma)
- Potential wage inflation impacting delivery costs
Key Highlights
Revenue from operations increased 39.7% YoY to ‑1,063.1 Cr, representing 30.3% of TTM revenue.
Active client base ($0.25M+ revenue) expanded by 50% YoY to 105 clients.
Revenue per Employee (RPE) improved 14.2% YoY to $77.1K, indicating higher operational efficiency.
Client concentration in the Top 20 accounts reduced significantly to 66.6% from 76.2% YoY.
Enterprise Commercial Solutions segment grew 44% YoY, now contributing 70.6% of total revenue.
👀 What to Watch
Monitor the trajectory of EBITDA margins in upcoming quarters to see if they return to the 18-20% historical range as recent investments in sales and GenAI platforms mature. Watch for the execution of the 'Content Super App' and other AI-native products as drivers for future operating leverage.
39.7% YoY Revenue Growth in Q1 FY27; Active Clients Cross 100 Milestone
Indegene reported a strong start to FY27 with Q1 revenue reaching ₹1,063.1 Cr, a 39.7% YoY increase. While PAT grew 45.9% sequentially to ₹116.2 Cr, PAT margins at 10.9% remain lower than the 15.3% recorded in the same quarter last year. The company successfully expanded its active client base to 105, adding 14 clients sequentially, and increased its high-value $10M+ customer count to 12. Management noted this was the strongest first-quarter sequential USD revenue growth (2.5%) in four years.
Confidence: HIGH
What changedIndegene achieved its strongest Q1 sequential growth in four years and reached a milestone of over 100 active clients.
Why it mattersThe results validate the company's strategy of investing in sales and go-to-market teams, showing that these investments are converting into both new client acquisitions and deeper penetration of existing large accounts.
Q1 Revenue: ₹1,063.1 CrYoY Revenue Growth: 39.7%Q1 PAT: ₹116.2 CrEBITDA Margin: 16.9%Active Clients: 105Revenue vs TTM Revenue: 30.3%
📅 Short termThe stock is likely to react positively to the strong top-line growth and the sequential recovery in margins after a dip in the previous quarter.
📈 Long termThe company is well-positioned in the growing life sciences outsourcing market, with structural growth driven by its ability to scale large $10M+ accounts and integrate AI into commercialization workflows.
⚠ Risk flags
- Year-on-year margin compression (EBITDA margin fell from 20.2% to 16.9% YoY)
- High client concentration with top 20 biopharma companies contributing 65.5% of revenue
Key Highlights
Revenue from operations grew 39.7% YoY to ₹1,063.1 Cr, representing ~30% of TTM revenue in a single quarter.
Active client base crossed the 100-milestone, reaching 105 clients with 14 additions in the quarter.
PAT recovered significantly on a sequential basis, rising 45.9% from ₹79.7 Cr in Q4 FY26 to ₹116.2 Cr.
Revenue per Employee (RPE) strengthened to $77.1K, which the company claims is the highest among its peer group.
Large-scale accounts ($10M+ annual revenue) expanded by 2 sequentially to reach a total of 12 customers.
👀 What to Watch
Watch for the promised improvement in operating leverage and profitability in the second half of FY27 as recent sales investments mature. Monitor if EBITDA margins can trend back toward the 20% levels seen in early FY26.
Indegene Q1 Revenue Grows 39.7% YoY to ₹1,063 Cr; 12,451 ESOP Shares Allotted
Indegene reported a robust 39.7% YoY revenue growth in Q1 FY27, reaching ₹1,063.1 crore, up from ₹760.8 crore in the previous year. However, Net Profit remained stagnant at ₹116.2 crore compared to ₹116.4 crore YoY, reflecting margin pressure as employee expenses surged 36.8% to ₹659.1 crore. The company also confirmed the full utilization of its ₹724.6 crore IPO proceeds and the allotment of 12,451 shares under its ESOP scheme.
Confidence: HIGH
What changedIndegene released its Q1 FY27 financial results showing strong top-line growth but flat profitability, alongside completing its IPO fund utilization.
Why it mattersThe results highlight a significant scale-up in operations (nearly 40% revenue growth) but also underscore the challenge of rising costs in the life sciences services sector, which is currently capping profit growth.
Q1 Revenue: ₹1,063.1 CrYoY Revenue Growth: 39.7%Q1 Net Profit: ₹116.2 CrEmployee Expense Ratio: 62%IPO Proceeds Utilized: ₹724.6 CrProposed Dividend: ₹2.25 per share
📅 Short termThe stock may see mixed reactions as the market weighs impressive revenue growth against stagnant net profit and high operating expenses.
📈 Long termThe company's expansion into mid-sized pharma and AI-integrated platforms supports long-term growth, but margin recovery is essential for a structural re-rating.
⚠ Risk flags
- High employee cost concentration
- Stagnant YoY net profit despite high revenue growth
- High client concentration with top 20 biopharma contributing 65.5% of revenue
Key Highlights
Revenue from operations rose to ₹1,063.1 crore in Q1 FY27, a 39.7% increase over Q1 FY26.
Net profit for the quarter was ₹116.2 crore, showing a marginal decline from ₹116.4 crore in the year-ago period.
Employee benefit expenses reached ₹659.1 crore, accounting for 62% of total revenue for the quarter.
The company successfully utilized the entire ₹724.6 crore of net IPO proceeds as of June 30, 2026.
Board approved the allotment of 12,451 equity shares under the ESOP Scheme 2020.
👀 What to Watch
Investors should monitor the company's ability to translate high revenue growth into bottom-line profits, specifically looking for stabilization in employee costs and integration benefits from recent acquisitions.
39.7% YoY Revenue Growth in Q1 FY27; PAT Remains Flat at ₹116.2 Cr
Indegene reported a strong 39.7% YoY revenue growth to ₹1,063.1 Cr for Q1 FY27, driven by its life sciences commercialization services. However, net profit remained flat at ₹116.2 Cr compared to ₹116.4 Cr in the same quarter last year, indicating significant margin compression. The company has now fully utilized its IPO proceeds of ₹724.6 Cr, primarily for debt repayment and growth initiatives. Operating margins declined to approximately 16.4% from 20.4% in the year-ago period, largely due to a 36.9% increase in employee benefit expenses.
Confidence: HIGH
What changedThe company has reported its first quarter of FY27, showing continued strong top-line momentum but stagnant bottom-line growth due to rising costs.
Why it mattersThe flat profit despite high revenue growth suggests that the company is currently in a high-investment phase for talent and technology, which is testing its operating leverage.
Revenue (Q1 FY27): ₹1,063.1 CrYoY Revenue Growth: 39.7%Net Profit (Q1 FY27): ₹116.2 CrEmployee Expense as % of Revenue: 62.0%IPO Proceeds Utilized: 100%
📅 Short termThe market may react positively to the robust revenue growth, but the lack of profit growth and margin contraction could limit any significant upside in the near term.
📈 Long termThe structural growth in life sciences outsourcing remains intact; long-term value depends on the company's ability to convert its growing scale into higher profitability.
⚠ Risk flags
- Margin compression
- High employee cost concentration
- Client concentration (top 20 biopharma contribute 65.5% of revenue)
Key Highlights
Revenue from operations grew 39.7% YoY to ₹1,063.1 Cr from ₹760.8 Cr.
Net profit for the quarter stood at ₹116.2 Cr, nearly identical to the ₹116.4 Cr reported in Q1 FY26.
Employee benefit expenses rose sharply to ₹659.1 Cr, representing 62% of total revenue.
IPO proceeds of ₹724.6 Cr are now 100% utilized as of June 30, 2026.
Proposed final dividend of ₹2.25 per equity share for FY26 is pending shareholder approval.
👀 What to Watch
Investors should monitor the company's ability to recover operating margins as it integrates recent acquisitions and scales its AI-integrated platforms. Watch for management commentary regarding wage inflation and the impact of US drug pricing policies on client spending.
₹2.25 Final Dividend Proposed; Indegene Schedules 28th AGM for August 13
Indegene Limited has scheduled its 28th Annual General Meeting (AGM) for August 13, 2026, to approve the FY26 financial statements and a final dividend of ₹2.25 per equity share. The company reported a TTM revenue of ₹3,510 Cr and a PAT of ₹401 Cr, maintaining a healthy operating margin of 17.6%. Key agenda items include the re-appointment of CEO Manish Gupta and the appointment of Ms. Jill Mary De Simone as an Independent Director. Shareholders as of the August 7, 2026 cut-off date will be eligible to vote on these resolutions.
Confidence: HIGH
What changedThe company has formalized the schedule for its 28th AGM and officially proposed a final dividend of ₹2.25 per share for shareholder approval.
Why it mattersThe AGM is the primary forum for shareholders to approve the company's financial performance and leadership changes, while the dividend confirms the company's ability to return cash to shareholders from its ₹401 Cr annual profit.
Final Dividend: ₹2.25 per shareDividend Yield (at ₹510.9): 0.44%TTM Revenue: ₹3510 CrTTM PAT: ₹401 CrCut-off Date: August 7, 2026
📅 Short termThe stock may see minor positive sentiment leading up to the dividend record date, though the yield is relatively low at current market prices.
📈 Long termThe company's focus on scaling its Enterprise Commercial segment (26.2% YoY growth) and AI integration remains the primary structural driver beyond routine AGM matters.
⚠ Risk flags
- High client concentration with 65.5% revenue from top 20 biopharma
- Potential margin pressure from US policy changes like the Inflation Reduction Act (IRA)
Key Highlights
Final dividend of ₹2.25 per equity share (face value ₹2) proposed for the financial year ended March 31, 2026
AGM scheduled for August 13, 2026, with a voting cut-off date fixed for August 7, 2026
Top 20 global biopharma companies contribute 65.5% of the company's total revenue
TTM Revenue stands at ₹3,510 Cr with a net profit of ₹401 Cr for the same period
Appointment of Ms. Jill Mary De Simone as an Independent Director for a 3-year term starting January 22, 2026
👀 What to Watch
Investors should note the cut-off date of August 7, 2026, for dividend eligibility and monitor the AGM proceedings for updates on the integration of recent acquisitions like BioPharm and WARN & Co.
₹2.25 Final Dividend: Indegene Sets July 31 as Record Date
Indegene Limited has fixed July 31, 2026, as the record date for a final dividend of ₹2.25 per equity share for the financial year ended March 31, 2026. This dividend, representing a 112.5% payout on the face value of ₹2, is subject to shareholder approval at the upcoming 28th Annual General Meeting (AGM) scheduled for August 13, 2026. Additionally, the company announced the reconstitution of its Audit, Risk Management, and Investment committees effective July 15, 2026, to align with changes in board composition.
Confidence: HIGH
What changedIndegene has formalized the timeline for its FY26 final dividend payment and updated its internal board committee structures.
Why it mattersThe announcement provides certainty regarding the timing of shareholder payouts and demonstrates routine corporate governance through committee updates.
Final Dividend: ₹2.25 per shareDividend Yield: 0.44%Record Date: 31-Jul-2026AGM Date: 13-Aug-2026Face Value: ₹2
📅 Short termThe stock is likely to see routine trading activity around the record date as investors position for the dividend payout.
📈 Long termLimited; this is a routine administrative and dividend announcement that does not alter the company's structural growth trajectory in life sciences outsourcing.
Key Highlights
Final dividend of ₹2.25 per equity share recommended for FY26
Record date for dividend eligibility fixed as July 31, 2026
28th Annual General Meeting (AGM) to be held on August 13, 2026
Dividend yield stands at approximately 0.44% based on the current price of ₹511.0
Reconstitution of 3 board committees including Audit and Risk Management
👀 What to Watch
Investors seeking the dividend must hold the shares before the ex-dividend date (typically one business day prior to the July 31 record date). Monitor the AGM on August 13 for management commentary on the integration of recent acquisitions like BioPharm and WARN & Co.
Indegene Reports FY26 Revenue of ₹35.1 Bn with 29.4% 5-Year CAGR
Indegene Limited has released a comprehensive investor presentation highlighting its FY26 performance, featuring revenue of INR 35.1 billion and a 29.4% CAGR since FY21. The company maintains a strong financial profile with an adjusted EBITDA margin of 19.4% and a zero-debt balance sheet. Strategically, Indegene is positioning itself as a key AI-embedded partner for the top 20 global pharmaceutical companies, aiming to capture a significant share of the $100 billion projected outsourced life sciences market by 2030.
Key Highlights
Revenue reached INR 35,105 million in FY26, growing at a 29.4% CAGR over five years.
Maintained high cash efficiency with an OCF to PAT ratio of 162% and an adjusted EBITDA margin of 19.4%.
Client base expanded to 91 active relationships, with revenue from Top-20 pharma clients tripling since FY21 to INR 25.2 billion.
Revenue per employee stands at $74.7K, supported by a Net Revenue Retention (NRR) consistently above 100%.
Targeting a $54B to $100B market opportunity driven by the centralization of pharma sales and marketing functions through AI.
👀 What to Watch
Investors should note the company's strong cash conversion and zero-debt status, which provides significant headroom for its M&A-led growth strategy. The focus on AI-driven centralization in pharma marketing suggests a sustainable competitive advantage over traditional agencies.
Indegene Reports FY26 Revenue of ₹35.1Bn with 29.4% 5-Year CAGR and 19.4% EBITDA Margin
Indegene Limited has presented a robust growth trajectory with FY26 revenue reaching INR 35,105 million, supported by a 29.4% CAGR over the last five years. The company maintains a strong financial profile with a 19.4% adjusted EBITDA margin, zero debt, and a high OCF to PAT ratio of 162%. Strategically positioned as an AI-embedded partner for the life sciences industry, Indegene serves all of the top 20 global pharmaceutical companies and enters FY27 with a pipeline 17% higher than the previous year.
Key Highlights
Achieved FY26 revenue of INR 35,105 million with a 5-year CAGR of 29.4% and PAT CAGR of 16.7%.
Maintains a debt-free balance sheet with an adjusted EBITDA margin of 19.4% and Revenue per Employee of $74.7K.
Top-20 client revenue grew 3.0x between FY21 and FY26, with Net Revenue Retention consistently above 100%.
The outsourced life sciences operations market is projected to grow from $54B in 2024 to ~$100B by 2030.
FY27 starting pipeline is 17% higher than the previous year, driven by strength in both Top-20 and mid-tier pharma cohorts.
👀 What to Watch
Investors should consider Indegene a strong long-term play in the life sciences technology sector due to its high cash conversion and dominant position with global pharma majors. The company's focus on AI-driven centralization of sales and marketing spend offers a significant structural growth tailwind.
Indegene FY26 Revenue Crosses ₹3,500 Cr; Q4 Hits Record ₹1,000 Cr Milestone
Indegene reported a strong FY26 with annual revenue reaching ₹35,105 million, a 23.6% YoY growth in INR terms. The company achieved a significant milestone in Q4, with quarterly revenue exceeding ₹1,000 crores for the first time in its history. Growth was driven by deepening relationships with top 20 global pharma firms and a 30% increase in customers contributing over $1 million. Management highlighted a major productivity boost, with revenue per employee rising to $75,000, supported by GenAI-led innovation and outcome-based pricing models.
Key Highlights
FY26 revenue grew 23.6% YoY to ₹35,105 million, with Q4 revenue crossing the ₹1,000 crore mark.
Active customer base expanded from 73 to 91, with 53 customers now contributing over $1 million in annual revenue.
Revenue per employee increased to $75,000 from $56,000 three years ago, driven by AI integration and 'Transform AI' program.
Secured a multi-year omnichannel deal exceeding $10 million in ACV and a strategic 'Tectonic' engagement with its largest client.
Demonstrated GenAI capability by reducing agency-style creative workflows from 3 months to just 3 days in pilot programs.
👀 What to Watch
Investors should view the strong revenue growth and productivity gains as a sign of successful AI adoption and market leadership in life sciences services. Monitor the conversion of the $10M+ ACV deal and the potential for the largest client to hit the $50M mark in FY27 as key growth catalysts.
Indegene Receives Income Tax Demand of ₹43.69 Crore for AY 2023-24
Indegene Limited has received a final assessment order from the Income Tax Department for Assessment Year 2023-24, raising a demand of INR 43.69 crore including interest. The demand stems from transfer pricing adjustments totaling INR 123.41 crore made to the company's returned income. Indegene is contesting the order through the Mutual Agreement Procedure (MAP) under the India-USA Double Taxation Avoidance Agreement and domestic appellate channels. The company expects no material adverse impact on its financial position or operations from this development.
Key Highlights
Total income tax demand of INR 43,68,84,410 (approx. ₹43.69 Cr) including interest.
Transfer pricing adjustments made to returned income amount to INR 123,41,10,559 (approx. ₹123.41 Cr).
Assessment pertains to AY 2023-24, corresponding to the Financial Year 2022-23.
Company has filed for resolution via Mutual Agreement Procedure (MAP) under India-USA DTAA.
Management maintains that current tax positions are well-supported and expects no material liability.
👀 What to Watch
Investors should monitor the outcome of the MAP and domestic appeals, as transfer pricing disputes are common for global service firms and often take time to resolve. No immediate action is required as the company is actively contesting the demand.
Indegene Named Leader in ISG Provider Lens for Life Sciences Digital Services for 3rd Year
Indegene has been recognized as a Leader in the ISG Provider Lens 2026 report for Life Sciences Digital Services, marking its third consecutive year in this position. The recognition highlights the company's expertise in using AI and GenAI through its proprietary NEXT and Cortex platforms to modernize commercial operations for biopharma firms. Indegene currently serves the world's top 20 biopharma companies, providing integrated, data-driven commercial models. This validation by a global research firm reinforces Indegene's competitive moat in a highly specialized and regulated niche.
Key Highlights
Recognized as a Leader in ISG Provider Lens for the 3rd consecutive year
Proprietary platforms NEXT and Cortex highlighted for AI and GenAI integration
Indegene serves the world's top 20 biopharma companies globally
Focus on digital evolution across planning, content, engagement, and analytics
👀 What to Watch
This recognition validates Indegene's technological leadership; investors should monitor if this helps secure larger contracts or higher margins within the global biopharma sector.
Indegene FY26 Results: Rs 2.25 Final Dividend Declared; 52,951 ESOP Shares Allotted
Indegene Limited has announced its audited financial results for the quarter and full year ended March 31, 2026. The Board recommended a final dividend of Rs. 2.25 per equity share (112.5% of face value), subject to shareholder approval. Additionally, the company approved the allotment of 52,951 securities under its ESOP and RSU 2020 schemes. The statutory auditors, Deloitte Haskins & Sells, have issued an unmodified opinion on the consolidated financial statements, indicating no major accounting discrepancies.
Key Highlights
Recommended a final dividend of Rs. 2.25 per equity share of Rs. 2 each for FY 2025-26
Allotted 52,951 securities pursuant to ESOP Scheme 2020 and RSU Scheme 2020
Audited standalone and consolidated financial results for Q4 and FY26 approved with an unmodified opinion
Approved amendments to 19 key corporate policies including Insider Trading and Risk Management
Dividend payment to be completed within 30 days post-approval at the ensuing AGM
👀 What to Watch
Investors should monitor the record date for the Rs. 2.25 dividend and review the detailed P&L statement to assess margin trends. The clean audit report and consistent dividend payout reflect stable corporate governance.
Indegene Recommends Final Dividend of ₹2.25 per Share for FY26
Indegene Limited's Board of Directors has recommended a final dividend of ₹2.25 per equity share (face value ₹2) for the financial year ended March 31, 2026. The company also approved its audited financial results for the quarter and full year, which received an unmodified audit opinion from Deloitte. The dividend is subject to shareholder approval at the upcoming Annual General Meeting and will be paid within 30 days of such approval. Additionally, the board approved allotments under ESOP and RSU schemes and updated several corporate policies.
Key Highlights
Recommended a final dividend of ₹2.25 per equity share of ₹2 each for FY26.
Audited standalone and consolidated financial results for FY26 approved with an unmodified audit opinion.
Dividend payment to be completed within 30 days of shareholder approval at the AGM.
Approved allotments under ESOP Scheme 2020 and RSU Scheme 2020.
Comprehensive review and amendment of 19 corporate policies including Dividend Distribution and Risk Management.
👀 What to Watch
Investors should track the announcement of the record date to ensure eligibility for the ₹2.25 dividend. The unmodified audit report on annual results suggests stable financial reporting and governance.
Indegene FY26 Revenue Surges 23.6% to ₹3,510 Cr; Recommends ₹2.25 Dividend
Indegene reported a strong FY26 with revenue growing 23.6% YoY to ₹35,105 million, marking its strongest growth in three years. Adjusted EBITDA stood at ₹6,793 million with a steady margin of 19.4%, while the company achieved a high cash conversion with OCF to PAT at 162%. The company significantly expanded its client base to 91 active relationships, including 53 accounts generating over $1 million in revenue. Management highlighted the successful integration of acquisitions and a robust GenAI-led pipeline heading into FY27.
Key Highlights
Revenue re-accelerated to 23.6% growth in FY26 compared to 9.6% in FY25, crossing the ₹1,000 crore quarterly mark in Q4.
Adjusted EBITDA grew 20.8% YoY to ₹6,793 million, maintaining a resilient margin profile between 19-20%.
The $1M+ revenue client base expanded by 29% YoY to 53 accounts, the highest addition in four years.
Revenue productivity improved by 11.8% to $74.7K per employee, driven by operational leverage and GenAI scaling.
Board recommended a final dividend of ₹2.25 per share, representing a 12.5% increase over the previous year.
👀 What to Watch
Investors should note the strong re-acceleration in revenue and high cash conversion as signs of operational strength. The company's successful expansion of its $1M+ client base and rising revenue per employee suggest a scalable business model with high earnings quality.
Indegene Q4FY26 Revenue Jumps 32.8% YoY; Crosses ₹3,500 Cr Annual Revenue Milestone
Indegene reported a strong Q4 FY26 with quarterly revenue crossing the ₹1,000 crore mark for the first time, reaching ₹1,003.4 crore. For the full year FY26, revenue grew 23.6% to ₹3,510.5 crore, supported by 53 clients contributing over $1 million in annual revenue. While annual Adjusted EBITDA margins saw a slight compression to 19.4%, cash flow from operations surged by 47.3% YoY to ₹6,508 million. The board has recommended an increased final dividend of ₹2.25 per share.
Key Highlights
Quarterly revenue grew 32.8% YoY to ₹1,003.4 crore, surpassing the ₹1,000 crore milestone.
Full-year FY26 revenue reached ₹3,510.5 crore, representing a 23.6% YoY growth in INR terms.
Cash flow from operations increased by 47.3% YoY to ₹6,508 million with a 162% cash conversion ratio.
Board recommended a final dividend of ₹2.25 per equity share, a 12.5% increase over the previous year.
Strong deal momentum in Q4 with 1 deal over $3M ACV and 7 deals in the $1-3M range.
👀 What to Watch
Investors should take note of the robust revenue growth and exceptional cash flow generation which underscores the company's operational efficiency. The stock remains a strong play in the life sciences digital transformation space, though monitoring margin stability in upcoming quarters is advised.
Indegene Recommends Rs 2.25 Final Dividend and Approves FY26 Audited Results
Indegene Limited's Board has approved the audited financial results for the quarter and full year ended March 31, 2026. The company recommended a final dividend of Rs. 2.25 per equity share (112.5% of face value), subject to shareholder approval at the upcoming AGM. The statutory auditors, Deloitte Haskins & Sells, issued an unmodified opinion on the financial statements, confirming a clean audit. Additionally, the Board approved share allotments under ESOP and RSU schemes and updated several key corporate governance policies.
Key Highlights
Recommended a final dividend of Rs. 2.25 per equity share of Rs. 2 each for FY 2025-26.
Approved audited standalone and consolidated financial results for the year ended March 31, 2026.
Statutory auditors issued an unmodified opinion on the financial results, indicating no accounting discrepancies.
Approved share allotments under the ESOP Scheme 2020 and RSU Scheme 2020.
Amended 19 internal policies including Insider Trading, CSR, and Risk Management to align with regulations.
👀 What to Watch
Investors should look out for the announcement of the AGM and record date to be eligible for the Rs 2.25 dividend. The clean audit report and dividend payout reflect stable governance and a commitment to returning value to shareholders.
Indegene to Acquire Two UK Entities for GBP 2.7 Million in Internal Restructuring
Indegene Limited is streamlining its corporate structure by acquiring 100% equity in two UK-based subsidiaries, DT Associates Research and Consulting Services and Trilogy Writing and Consulting, for a combined cash consideration of approximately GBP 2.7 million. This internal restructuring will bring both entities under Indegene Healthcare UK Limited. DT UK reported FY25 revenue of GBP 6.4 million, while Trilogy UK reported GBP 2.34 million. The transaction is expected to be completed by March 31, 2026, and is classified as a related party transaction conducted at arm's length.
Key Highlights
Acquisition of 100% stake in DT UK for GBP 2,001,000 and Trilogy UK for GBP 702,348
DT UK revenue declined to GBP 6.4 million in FY25 from GBP 9.2 million in FY24
Trilogy UK showed revenue growth, reaching GBP 2.34 million for the period ending March 2025
The move is primarily for internal restructuring to consolidate UK-based life science service operations
Total cash consideration for both acquisitions is approximately GBP 2.703 million
👀 What to Watch
Investors should view this as a routine corporate cleanup to simplify the subsidiary hierarchy. No immediate impact on consolidated financials is expected as the entities were already part of the group.
